MRNA

#567
Moderna, Inc. Common Stock
54.26 USD
+2.69%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
54.26
54.26
Faixa anual
22.29
59.55
Mudança diária
+2.69%
Mudança mensal
+1.42%
Mudança em 6 meses
+105.61%
Mudança anual
+114.64%
Fechamento anterior
52.84
Abrir
54.26
Bid
Ask
Mínimo
54.26
High
54.26
Volume
265
Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 21.43 B
  • Employee 4 700
  • Founded N/A
  • CEO Stéphane Bancel
  • Website www.modernatx.com
  • Headquarter Delaware, United States
  • FIGI BBG003PHHZT1
  • Industry Biotecnologia
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
-4.06
Índice preço/fluxo de caixa
5.9

Moderna Inc

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.

Notícias